In addition, LAVA-1207, a GammabodyTM targeting PSMA is tested in a phase I/IIa clinical trial (NCT05369000) in patients suffering from therapy-refractory metastatic castration-resistant prostate cancer. Here, FOLH1 is linked to prostate carcinoma.